Another bite at the cherry
Cherry Blossom at the Edinburgh Meadows
It is very rare indeed to see first generation anti-cancer molecules hit the sweet spot against any given novel target. Those following in their wake can often learn from the experiences of their forebears and adjust accordingly.
In our latest story, we look at one such IO target with a chequered history and highlight the next generation agents coming through.
Sometimes simply switching modalities or aiming at different cells/compartments is enough to do the trick. Other times a completely different strategy is needed to unlock the riches hoped for.
With a raft of new data coming soon at ASCO, are their some new diamonds in the rough this time around?
To learn more from our latest oncology expert interview and get a heads up on key cancer research insights, subscribers can log-in or you can click to gain access to BSB Premium Content.
This content is restricted to subscribers
